



Tirosint® (levothyroxine) – First-time authorized brand alternative

- On November 3, 2020, [Lannett Company launched](#) an authorized brand alternative of IBSA Institut Biochemique's [Tirosint \(levothyroxine\)](#) capsules.
 - Teva has received FDA approval of an [AB-rated](#) generic version of Tirosint on October 28, 2020. Launch plans for this product are pending.
- Tirosint is approved as a replacement therapy in adults and pediatric patients 6 years and older with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of adults and pediatric patients 6 years and older with thyrotropin-dependent well-differentiated thyroid cancer.
- Levothyroxine is also available as a generic [tablet](#), a generic [injection](#), and a brand oral solution ([Tirosint-SOL](#)).
 - Levothyroxine tablets and Tirosint-SOL carry the same indications as Tirosint capsules, but may be used in pediatric patients down to 0 months for hypothyroidism.
 - Levothyroxine injection is for the treatment of myxedema coma.
- Tirosint carries a boxed warning stating it is not for treatment of obesity or for weight loss.
- According to IQVIA, total U.S. sales for Tirosint capsules was \$111 million for the 12 months ending in September 2020



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.